Qiagen NV - Hilden, Germany-based molecular diagnostics company - Records net sales of USD500 million in the third quarter of 2022, down 7% year-on-year, as Covid-19 product group sales fell 43% at constant exchange rates to USD83 million amid reduced demand. Adjusted diluted earnings per share fall to USD0.53 compared to USD0.58 in the same period in 2021. Raises its full-year 2022 outlook based on the strong results in the first nine months to date. Expects net sales to be about USD2.25 billion at constant exchange rates, up from the prior outlook for at least USD2.2 billion. Expects adjusted diluted earnings per share to be about USD2.40 at constant exchange rates, up from for at least USD2.30.

Current stock price: EUR42.02

12-month change: down 11%

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.